NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The awards include 50,400 options and 15,400 restricted stock units to help NewAmsterdam recruit five non-executive hires.
- On Friday, May 1, 2026, NewAmsterdam Pharma Company announced that the Compensation Committee of its Board of Directors approved inducement grants for five new hires: 50,400 share options and 15,400 restricted stock units.
- These awards align with the NewAmsterdam 2024 Inducement Plan, structured to comply with Nasdaq Listing Rule 5635, which mandates shareholder approval for equity sales exceeding 20% of outstanding shares.
- Stock options carry a $28.43 exercise price, equal to the Nasdaq closing price on the grant date, vesting over four years with 25% after one year and the remainder in 36 equal monthly installments.
- Trading volume reached 1,407,566 shares, 1.58 times the 20-day average, while reported short interest stands at 7.93% of the float, indicating elevated investor activity surrounding this routine update.
- Similar inducement grants in March and April 2026 followed the same 2024 Inducement Plan structure, as NewAmsterdam continues investigating obicetrapib in phase 3 studies for patients at risk of cardiovascular disease.
21 Articles
21 Articles
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - NewAmsterdam Pharma
NAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
Aspen Daily News
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, May 1, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on April 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 28,450 shares of…
North Bay Nipissing
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia and BOSTON, MA, May 01, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement…
Coverage Details
Bias Distribution
- 56% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
